Skip to main content
Top
Published in: Osteoporosis International 1/2024

Open Access 26-09-2023 | Hypocalcemia | Original Article

Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection

Authors: Anna Spångeus, Johan Rydetun, Mischa Woisetschläger

Published in: Osteoporosis International | Issue 1/2024

Login to get access

Abstract

Summary

We assessed the prevalence of hypocalcemia after denosumab injections in a real-world cohort routinely monitored for calcium during up to 7.5 years of treatment. Among 1096 injections in 242 patients, 6.3% resulted in hypocalcemia, and was independent of the injection number. Severe hypocalcemia was rare (1%).

Purpose

To assess the prevalence of and risk factors for hypocalcemia after administration of denosumab in a patient cohort routinely monitored for ionized calcium after each dose.

Methods

In this retrospective observational study, we analyzed denosumab-induced hypocalcemia in a real-world cohort who were routinely followed up with ionized calcium pre- and post-injection (within 31 days after injection) during the period 2011 to 2020.

Results

In total, we included data from 1096 denosumab injections in 242 individuals (1–15 injections per patient). The mean age for the first injection was 74 ± 10 years, and 88% were female. Post-injection hypocalcemia occurred after 6.3% of all injections (4.6% mild, 0.6% moderate, and 1.1% severe) and was independent of the number of injections (rate of hypocalcemia varied from 3–8%). Risk factors for hypocalcemia were male sex, severe renal failure, pre-injection hypocalcemia, hypomagnesemia, hypophosphatemia, and vitamin D insufficiency. Furthermore, older age was not associated with an increased hypocalcemia risk.

Conclusions

Denosumab-induced hypocalcemia is a prevalent adverse event, which occurs independently of the number of injections. However, severe hypocalcemia is a rare occurrence, and severe renal failure and nutritional status appear to be important predictive factors. Magnesium and phosphate might add value in the pre-injection risk assessment; however, this observation needs to be confirmed in larger cohorts.
Appendix
Available only for authorised users
Literature
2.
go back to reference Emelie T, Jonas B, Åkesson K, Anna S, Gustaf O, Libanati C (2020) History of previous fracture and imminent fracture risk in Swedish women aged 55–90 years presenting with a fragility fracture. J Bone Miner Res 35:861–868CrossRef Emelie T, Jonas B, Åkesson K, Anna S, Gustaf O, Libanati C (2020) History of previous fracture and imminent fracture risk in Swedish women aged 55–90 years presenting with a fragility fracture. J Bone Miner Res 35:861–868CrossRef
3.
4.
go back to reference Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523CrossRefPubMed Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513–523CrossRefPubMed
5.
go back to reference Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44CrossRefPubMed Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44CrossRefPubMed
6.
go back to reference Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed
7.
go back to reference Tanaka S, Mizutani H, Tsuruya E, Fukuda R, Kuge K, Okubo N (2021) Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study. J Bone Miner Metab 39:463–473CrossRefPubMed Tanaka S, Mizutani H, Tsuruya E, Fukuda R, Kuge K, Okubo N (2021) Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study. J Bone Miner Metab 39:463–473CrossRefPubMed
8.
go back to reference Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T (2020) Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? Osteoporos Int 31:655–665CrossRefPubMed Tsvetov G, Amitai O, Shochat T, Shimon I, Akirov A, Diker-Cohen T (2020) Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low? Osteoporos Int 31:655–665CrossRefPubMed
9.
go back to reference Ishikawa K, Nagai T, Sakamoto K et al (2016) High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag 12:1831–1840CrossRefPubMedPubMedCentral Ishikawa K, Nagai T, Sakamoto K et al (2016) High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag 12:1831–1840CrossRefPubMedPubMedCentral
10.
go back to reference Kim KJ, Hong N, Lee S, Kim M, Rhee Y (2020) A simple-to-use score for identifying individuals at high risk of denosumab-associated hypocalcemia in postmenopausal osteoporosis: a real-world cohort study. Calcif Tissue Int 107:567–575CrossRefPubMed Kim KJ, Hong N, Lee S, Kim M, Rhee Y (2020) A simple-to-use score for identifying individuals at high risk of denosumab-associated hypocalcemia in postmenopausal osteoporosis: a real-world cohort study. Calcif Tissue Int 107:567–575CrossRefPubMed
11.
go back to reference Vautour L, Goltzman D (2019) Regulation of calcium homeostasis. In: Bilezikian J (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 9th edn. Whiley, New York, pp 165–172 Vautour L, Goltzman D (2019) Regulation of calcium homeostasis. In: Bilezikian J (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 9th edn. Whiley, New York, pp 165–172
12.
go back to reference Broadwell A, Chines A, Ebeling PR et al (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106:397–409CrossRefPubMed Broadwell A, Chines A, Ebeling PR et al (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106:397–409CrossRefPubMed
13.
go back to reference Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479CrossRefPubMed Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27:1471–1479CrossRefPubMed
14.
go back to reference Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161CrossRefPubMed Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161CrossRefPubMed
15.
go back to reference Burtis C, Ashwood E, Bruns D (2012) Tietz textbook of clinical chemistry and molecular diagnostics, 5th edn. Elsevier Saunders, St. Louis Burtis C, Ashwood E, Bruns D (2012) Tietz textbook of clinical chemistry and molecular diagnostics, 5th edn. Elsevier Saunders, St. Louis
16.
go back to reference CKD work group (2013) Kidney disease: improving global outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150 CKD work group (2013) Kidney disease: improving global outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–150
17.
go back to reference Rhee Y, Chang DG, Ha J et al (2022) Real-world safety and effectiveness of denosumab in patients with osteoporosis: a prospective, observational study in South Korea. Endocrinol Metab (Seoul) 37:497–505CrossRefPubMed Rhee Y, Chang DG, Ha J et al (2022) Real-world safety and effectiveness of denosumab in patients with osteoporosis: a prospective, observational study in South Korea. Endocrinol Metab (Seoul) 37:497–505CrossRefPubMed
18.
go back to reference Ong GSY, Walsh JP, Stuckey BGA et al (2012) The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab 97:3138–3145CrossRefPubMed Ong GSY, Walsh JP, Stuckey BGA et al (2012) The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab 97:3138–3145CrossRefPubMed
19.
go back to reference Strickling J, Wilkowski MJ (2019) Severe, symptomatic hypocalcemia due to denosumab administration: treatment and clinical course. Case Rep Nephrol Dial 9:33–41CrossRefPubMedPubMedCentral Strickling J, Wilkowski MJ (2019) Severe, symptomatic hypocalcemia due to denosumab administration: treatment and clinical course. Case Rep Nephrol Dial 9:33–41CrossRefPubMedPubMedCentral
20.
go back to reference Diker-Cohen T, Amitai O, Shochat T, Shimon I, Tsvetov G (2020) Denosumab-associated hypocalcemia: does gender play a role? Maturitas 142:17–23CrossRefPubMed Diker-Cohen T, Amitai O, Shochat T, Shimon I, Tsvetov G (2020) Denosumab-associated hypocalcemia: does gender play a role? Maturitas 142:17–23CrossRefPubMed
21.
go back to reference Khan A, Sbayi A, Schlingmann KP (2019) Magnesium homeostasis. In: Bilezikian JP (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 9th edn. Whiley, New York, pp 173–178 Khan A, Sbayi A, Schlingmann KP (2019) Magnesium homeostasis. In: Bilezikian JP (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 9th edn. Whiley, New York, pp 173–178
22.
go back to reference White KE, Econs MJ (2019) FGF23 and the regulation of phosphorus metabolism. In: Bilezikian JP (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 9th edn. Whiley, New York, pp 187–93 White KE, Econs MJ (2019) FGF23 and the regulation of phosphorus metabolism. In: Bilezikian JP (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 9th edn. Whiley, New York, pp 187–93
Metadata
Title
Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection
Authors
Anna Spångeus
Johan Rydetun
Mischa Woisetschläger
Publication date
26-09-2023
Publisher
Springer London
Published in
Osteoporosis International / Issue 1/2024
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-023-06926-0

Other articles of this Issue 1/2024

Osteoporosis International 1/2024 Go to the issue